about
Ovarian response to controlled ovarian hyperstimulation in women with cancer is as expected according to an age-specific nomogram.Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer.Selecting embryos with the highest implantation potential using data mining and decision tree based on classical embryo morphology and morphokinetics.Gonadotrophin-releasing hormone-antagonists vs long agonist in in-vitro fertilization patients with polycystic ovary syndrome: a meta-analysis.Intra- and interobserver variability of 2D and 3D transvaginal sonography in the diagnosis of benign versus malignant adnexal masses.Three-dimensional sonography for diagnosis of rectovaginal septum endometriosis: interobserver agreement.Systematic review of screening for trisomy 21 in twin pregnancies in first trimester combining nuchal translucency and biochemical markers: a meta-analysis.Concordance between prenatal ultrasound and autopsy findings in a tertiary center.Randomized, comparative pilot study of pituitary suppression with depot leuprorelin versus cetrorelix acetate 3 mg in gonadotropin stimulation protocols for oocyte donors.Maternal fasting glycemia and adverse pregnancy outcomes in a Mediterranean population.Should progesterone on the human chorionic gonadotropin day still be measured?Impact of Surgery on the Evolution of Uterine Sarcomas.Accuracy of three-dimensional ultrasound compared with magnetic resonance imaging in diagnosis of Müllerian duct anomalies using ESHRE-ESGE consensus on the classification of congenital anomalies of the female genital tract.Usefulness of oocyte accumulation in low ovarian response for PGS.Comparison of starting ovarian stimulation on day 2 versus day 15 of the menstrual cycle in the same oocyte donor and pregnancy rates among the corresponding recipients of vitrified oocytes.How does vitrification affect oocyte viability in oocyte donation cycles? A prospective study to compare outcomes achieved with fresh versus vitrified sibling oocytes.Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer.[Oncologic risk counselling unit. Selection of risk groups and results].Endometriosis and IVF: are agonists really better? Analysis of 1180 cycles with the propensity score matching.Early first-trimester free-β-hCG and PAPP-A serum distributions in monochorionic and dichorionic twins.Is the addition of the ductus venosus useful when screening for aneuploidy and congenital heart disease in fetuses with normal nuchal translucency?Antagonist rescue of agonist IVF cycle at risk of OHSS: a case series.Investigations into implantation failure in oocyte-donation recipients.Prospective, randomized, comparative study of leuprorelin + human menopausal gonadotropins versus ganirelix + recombinant follicle-stimulating hormone in oocyte donors and pregnancy rates among the corresponding recipients.Does culture medium influence offspring birth weight?Tumor size and lymph node status in multifocal breast cancer.Transvaginal ultrasound (TVS) versus Magnetic Resonance (MR) for diagnosing deep infiltrating endometriosis: a systematic review and meta-analysis.Long-term Results for Expectant Management of Ultrasonographically Diagnosed Benign Ovarian Teratomas.What is a difficult transfer? Analysis of 7,714 embryo transfers: the impact of maneuvers during embryo transfers on pregnancy rate and a proposal of objective assessment.Characterization of a suboptimal IVF population and clinical outcome after two IVF cycles.Reproductive outcomes in recipients are not associated with oocyte donor body mass index up to 28 kg/m2: a cohort study of 2722 cycles.Importance of a 5- versus 7-day pill-free interval in a GnRH antagonist protocol using corifollitropin alfa: a prospective cohort study in oocyte donors.Is it justified to transfer two embryos in oocyte donation? A pilot randomized clinical trial.Is AMH useful to reduce low ovarian response to GnRH antagonist protocol in oocyte donors?Elective single-embryo transfer in oocyte donation programmes: Should it be the rule?Replacing GnRH agonists with GnRH antagonists in oocyte recipient cycle did not adversely affect the pregnancy rates.GnRH antagonist rescue of a long-protocol IVF cycle and GnRH agonist trigger to avoid ovarian hyperstimulation syndrome: three case reports.Poor prognosis for ovarian response to stimulation: results of a randomised trial comparing the flare-up GnRH agonist protocol vs. the antagonist protocol.Could monopronucleated ICSI zygotes be considered for transfer? Analysis through time-lapse monitoring and PGS.Training Performance in Diagnosis of Congenital Uterine Anomalies With 3-Dimensional Sonography: A Learning Curve Cumulative Summation Analysis.
P50
Q33591882-27F43153-6097-4CB5-9764-EE419D4532CDQ36017990-3113DBDD-C192-495E-A6CA-D9A536862B2AQ36390301-447AC435-2084-4E09-A4F0-F57FCF99D5DEQ37813637-739E181E-A41F-4F36-AF0D-F0CCE4EA4F95Q37866214-E097AE26-554C-4762-BFE4-6F65DE920FBDQ38110259-F6D65893-3AC2-4C19-9857-1EBE3FFD02CFQ38219313-C5DBE462-8759-444C-8032-53EC6EC10E0AQ39218692-A40E6550-C262-4074-94B8-8D62A4C53E31Q39878035-9C2873C4-931D-4225-AE2A-988BF7CF0433Q40398705-0FD161BB-653A-4ADC-B6C9-4D064BFC763FQ40446123-5B9128B9-D734-424B-8126-DC345E83190AQ40839693-CF8067D5-E98A-4930-AEC6-68AF06464407Q41413404-A0D6E1EB-2A2F-4284-A11B-EF12A6569261Q41599423-F5F51919-9B1D-41E3-A4F9-9BC809349EB2Q41602149-FD1FB492-257A-4BA8-A901-4EA34260B99EQ41604304-198BA1DE-1706-455F-90A3-DD085D1615C3Q44007838-3B8C0F87-BDF3-41B5-BA18-DA8A41C47C6DQ44761489-430AD942-0D14-4AB0-953A-6FB02BDCA844Q44794874-467858A5-D924-446A-BC9F-4F2B053A0F52Q44894080-C8D58B9B-BB7C-44A1-93F7-89319C070957Q45915317-F4EA46C5-4597-4996-81BA-9E0D5C9EB546Q46134112-8F6DC992-BE36-484F-BCCE-6CDE18DC20D6Q46252316-3ABE9554-3B02-4FC0-B787-45BB6CC12C9CQ46669124-478D44C2-402D-4686-8872-273262D2508FQ47218715-E45ABE88-5BF7-4452-950B-7120253F5F2FQ47306281-82B47D73-4352-4B5E-B982-9434B52C41ECQ47445867-5FCFF8E1-6915-4D39-80A9-8B5DC438A367Q47640383-42E0F6D2-2CE6-45AA-8647-FE604234DF20Q48010368-8F40A376-45BA-4373-87C1-CB5CE9F23E12Q48134103-7DE7BBF0-013A-438E-8326-9A37D750BF8AQ48513567-A7F0820E-2506-49CF-9B02-5CB828665ABAQ48515283-2DBC702B-763E-458F-ABA4-39E335674BD2Q48575764-1776D21A-5A4A-4DDF-ABBA-927BC97F6856Q48623132-356342BF-41B1-468C-913B-E1347E1715BFQ48637981-6F8FE125-EE1D-48B6-9F34-B74A4276EEDBQ48669570-C41A42AA-3C5E-4ED9-ABFF-5A3580E7FFFFQ48675267-36EEF016-4C7C-4E56-8CA2-BF4F5CF47838Q48704532-023404C9-4FB6-4062-A55F-9CEDC4273A8CQ50438346-3661619A-586B-44AE-ABB5-81AD2C51229AQ50475128-133CB669-98A1-4436-94AB-BA861D525F5A
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Ignacio Rodríguez
@ast
Ignacio Rodríguez
@en
Ignacio Rodríguez
@es
Ignacio Rodríguez
@nl
Ignacio Rodríguez
@sl
type
label
Ignacio Rodríguez
@ast
Ignacio Rodríguez
@en
Ignacio Rodríguez
@es
Ignacio Rodríguez
@nl
Ignacio Rodríguez
@sl
altLabel
Ignacio Rodriguez Garcia
@en
Ignacio Rodriguez
@en
prefLabel
Ignacio Rodríguez
@ast
Ignacio Rodríguez
@en
Ignacio Rodríguez
@es
Ignacio Rodríguez
@nl
Ignacio Rodríguez
@sl
P1153
P106
P1153
36130556400
56610072700
7102747510
P21
P31
P496
0000-0002-6586-0111